A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

About the trial

Sponsor

AbbVie

Tested

Etentamig (drug), Lenalidomide (drug), Dexamethasone (drug), Daratumumab (drug), Dexamethasone (drug), Carfilzomib (drug), Mezigdomide (drug), Iberdomide (drug), ABBV-2001 (drug), Etentamig (drug), Pomalidomide (drug)

Dates

Started 2025-06-30; completion 2036-03

Results posted

Not yet

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM. Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 8 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Part…

From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $64,900 in research payments for this study in 2025 (5 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.